• Founded: 2016
  • Location: Foster City, CA
  • Employee range: 50 - 200
  • Clinical stage: NDA (China, partner: Genor)
  • Therapy area: Solid tumors
  • Drug types: ONC
  • Lead product: APL-501
  • Product link: https://www.apollomicsinc.com/pipeline/
  • Funding: $124M C Oct 2020; $100M B Jan 2019; $10M Aug 2016



job board

Short description:

Cancer medicines

Drug notes:

Also Clin1 (worldwide) solid tumors; APL-106 Clin3 AML (partner: GlycoMimetica); APL-502 Clin3 (China, partner: CTTQ) multiple cancers, Clin0 (worldwide) multiple cancers; APL-101 Clin2 multiple cancers; APL-122 Clin1 oncology; APL-102 Clin1 solid tumors; APL-108 Clin0 multiple myeloma; APL-810 Clin0 GI cancers; APL-801 RD oncology

Long description:

Apollomics is developing a suite of next-generation therapies to treat cancer. Developing clinical assets requires rigorous preclinical studies and mechanistic and scientific rationale whether the asset is to be used as a monotherapy, a combination therapy or both. Apollomics is using this approach to build a pipeline of therapeutics that fall into three categories: [1] anti-cancer enhancers, [2] tumor inhibitors and [3] immuno-oncology drugs. Apollomic’s lead candidate, APL-101, is a selective and potent, orally-available inhibitor of c-Met, which is overexpressed or mutated in several tumor types. Following successful preclinical and Phase 1 clinical trials, Apollomics is now testing APL-101 in patients with non-small cell lung cancer.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com